BIO Applauds House Passage of the 21st Century Cures ActNov 30 2016
Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:
|
|
BIO Responds to GAO Report Declaring RFS Will Not Meet GoalsNov 29 2016
BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels but we would observe that EPA has chilled investment in commercializing this technology.
|
|
BIO Welcomes EPA’s Final 2017 Renewable Fuel StandardsNov 23 2016
The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and cellulosic biofuels.
|
|
BIO Statement on FDA Product Communications HearingNov 9 2016
BIO President and CEO Jim Greenwood released the following statement today regarding the FDA’s hearing on product communications:
“In the era of data-driven medicine, where all parties seek more, not less, information about the safety, effectiveness, and value of treatments, fostering informed communications among all stakeholders is critical. We are in the midst of a transition to value-based healthcare – a transition that has the potential to improve the efficiency of the overall healthcare system. Earlier this year, BIO and its members endorsed a systemic set of principles and commitments in support of moving us toward a value-based system – the first major healthcare industry association to do so.
|
|
BIO Patient and Health Advocacy Summit Hosts Over 300 Attendees from Wide Range of Health Care OrganizationsNov 4 2016
Over 200 diverse groups were represented at the November 3-4 meeting in Washington, D.C.
|
|
BIO Issues Call for Papers for 2017 World Congress on Industrial Biotechnology in MontréalNov 1 2016
BIO has officially issued a call to leaders from the biotechnology, bioenergy, chemical, consumer products manufacturing, and agricultural industries as well as academia and financial sectors industries to submit panel session proposals for the 2017 World Congress on Industrial Biotechnology. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada.
|
|
BIO Asks Congress to Extend Critical Bioenergy Tax Credits During Lame-DuckOct 18 2016
BIO today sent a letter to Congressional Leadership, the Senate Finance Committee Chairs, and the House Ways and Means Committee Chairs calling for the extension of renewable energy tax credits slated to expire at the end of 2016. In its letter, BIO urges Congress to advance a multi-year extension of the Second Generation Biofuel Producer Tax Credit, the Special Depreciation Allowance for Second Generation Biofuel Plant Property, the Biodiesel and Renewable Diesel Fuels Credit, and the Alternative Fuel Vehicle Refueling Property.
|
|
BIO Names Dana O’Brien Executive Vice President for Food & Agriculture SectionOct 13 2016
BIO announced today that Dana O’Brien has been named BIO’s Executive Vice President for its Food & Agriculture Section.
|
|
New BIO Report Dispels the Myth of the Blend Wall and High RIN PricesOct 4 2016
Data recently released by EPA on compliance with the Renewable Fuel Standard between 2010 and 2013 (the latest year for which compliance is complete) challenges the widely accepted assumption that the blend wall – the point at which ethanol blending in gasoline exceeds 10 percent – caused the 2013 spike in Renewable Identification Number (RIN) spot market prices.
|
|
BIO Statement on Biosimilar User Fee Act Goals LetterSep 26 2016
Washington, D.C. (September 16, 2016) – Biotechnology Innovation Organization (BIO) Senior Vice President for Science Policy Kay Holcombe released the following statement today regarding the Biosimilar User Fee Act (BsUFA) II goals letter:
|
